Deferasirox, an iron chelator, impacts myeloid differentiation by modulating NF-kB activity via mitochondrial ROS

Deferasirox (DFX) can improve erythropoiesis in patients with MDS. We sought to test how these changes occur and whether myelopoiesis broadly is affected by analyzing neutrophils and neutrophil precursors treated with DFX. We cultured human, LIN- bone marrow and peripheral blood cells in media containing GCSF for 5 days while treating with either DMSO, 1.5 uM DFX, or 3 uM DFX.